Ardelyx (ARDX) Competitors

ADMA Biologics (NASDAQ:ADMA) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.

Is ADMA or ARDX more profitable?

ADMA Biologics has a net margin of 17.80% compared to Ardelyx's net margin of -11.73%. ADMA Biologics' return on equity of 53.20% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	17.80%	53.20%	26.07%
Ardelyx	-11.73%	-24.87%	-10.51%

Do analysts recommend ADMA or ARDX?

ADMA Biologics presently has a consensus target price of $22.50, suggesting a potential upside of 11.06%. Ardelyx has a consensus target price of $10.95, suggesting a potential upside of 122.11%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Ardelyx	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Do institutionals and insiders believe in ADMA or ARDX?

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 5.9% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has higher earnings and valuation, ADMA or ARDX?

ADMA Biologics has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	11.23	-$28.24M	$0.82	24.71
Ardelyx	$333.62M	3.52	-$39.14M	-$0.16	-30.81

Does the media prefer ADMA or ARDX?

In the previous week, ADMA Biologics had 12 more articles in the media than Ardelyx. MarketBeat recorded 16 mentions for ADMA Biologics and 4 mentions for Ardelyx. ADMA Biologics' average media sentiment score of 1.34 beat Ardelyx's score of 0.70 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor ADMA or ARDX?

Ardelyx received 123 more outperform votes than ADMA Biologics when rated by MarketBeat users. However, 72.13% of users gave ADMA Biologics an outperform vote while only 67.46% of users gave Ardelyx an outperform vote.

Company	Underperform	Outperform
ADMA Biologics	Outperform Votes 414 72.13%	Underperform Votes 160 27.87%
Ardelyx	Outperform Votes 537 67.46%	Underperform Votes 259 32.54%

Which has more volatility & risk, ADMA or ARDX?

ADMA Biologics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Summary

ADMA Biologics beats Ardelyx on 13 of the 19 factors compared between the two stocks.